Φορτώνει......

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Oncogene
Κύριοι συγγραφείς:	Hata, Aaron N, Rowley, Steve, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Ji, Fei, Jung, Joonil, Light, Madelyn, Lee, Joon Sang, Debussche, Laurent, Sidhu, Sukhvinder, Sadreyev, Ruslan I, Watters, James, Engelman, Jeffrey A
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	2017
Θέματα:	Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5700857/ https://ncbi.nlm.nih.gov/pubmed/28783173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.258
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Παρόμοια τεκμήρια